aurelinate · Immunology · Oral selective JAK1/TYK2 inhibitor for moderate-to-severe atopic dermatitis.
1 objectives · 1 not started
| Objective | Product | Owner | Status | Progress | Confidence |
|---|---|---|---|---|---|
| SO-ARL-01Map and begin engaging the dermatology KOL landscape in US and EU ahead of Phase III readout. | Aurelin | TFDr. Tomás Ferreira | Not started | 12% | Medium |
Initiative status mix per product; mean initiative progress alongside.
Cross-functional review
1 initiatives · 10% mean progress
Status order: Completed · In progress · Planned · Not started · At risk · Blocked. Colours follow the status label shown in each legend.
Top 8 topics by insight count (duplicates excluded). Trend compares the last 60 days with the prior 60 days.
| Theme | Insights | Mean priority | Critical / High | Open high-priority | Trend (60d) |
|---|---|---|---|---|---|
| Adolescent population | 1 | 63 | 100% | 0 | Flat 0 vs 0 |
| Phase IIb efficacy | 1 | 58 | 0% | 0 | Flat 0 vs 0 |
0 initiatives at risk or blocked · 0 overdue tasks and actions
Nothing at risk or overdue in this scope
Submitted and reviewed engagements, FY2026 to date.
By stakeholder tier
Mean quality rating (1–5)
Mean 3.3 across 14 rated engagements: 1★ 0 · 2★ 0 · 3★ 8 · 4★ 5 · 5★ 1
Unique stakeholders
9
14 engagements
Tier 1 covered (6 mo)
2 / 3
67%
In person / virtual / phone
8 / 3 / 3
21% virtual
With ≥ 1 insight
2
14%
SLA compliance (MET-041) · target 92% · monthly, global scope
Jan 93.1% · Feb 92.4% · Mar 91.8% · Apr 92% · May 91.2% · Jun 90.6% · Jul 89.9% · Aug 89.4% · Sep 90.2%
The trend line is global; the counts below follow the selected scope.
Inquiries YTD
91
Open
3
Overdue
0
Breached (closed)
25
Escalated / safety
1 / 0
1 active publications · 0 of 0 planned submissions to date are submitted or beyond
Delayed milestones (0)
No publication milestones are past due.
1 projects · 0 active · 0 active at high risk
Idea 1
By evidence gap
| Evidence gap | Projects | Active | Budget |
|---|---|---|---|
| Long-term safety versus existing JAK inhibitors | 1 | 0 | $180k |
Weighted completion across scorecard dimensions. Grey dimensions carry no score; stale dimensions were last reviewed more than 30 days ago.
No launch scorecard for this product
Scorecards exist for products in launch or pre-launch.
FY2026 · planned $1.1M · committed $750k · actual $524k (49% consumed) · 0 lines at overrun risk
| Product | Planned | Committed | Actual | Consumed | Lines at risk |
|---|---|---|---|---|---|
| Aurelin | $1.1M | $750k | $524k | 49% | None |
0 teams · 0 over-allocated
No team exceeds its capacity in this scope.
1 decision proposed or under review
Plan in cross-functional review since 2026-09-08.
Recommendation: Approve · Impact: Plan becomes active · Approvers: Dr. Helen Okafor
Tenant-wide; not narrowed by product or region.
Open DQ issues
14
3 high · 7 medium · 4 low
Integrations degraded / failed
2
Veeva CRM (Degraded), Veeva Vault CTMS (Failed)
AI outputs pending review
3
INS-0061, INS-0060, RPT-Q3-EXEC
Metrics with DQ warnings
0
None
helixor-private-llm-2026.08 · generated 2026-09-15 06:00 UTC · scope: Aurelin · All regions · unapproved narratives are never distributed
Human review required
Strategic objectives
0 of 1 objectives are on track; 0 are at risk or off track. Mean progress is 12% against a 70% year-end target.
Sources:MET-001
Initiatives at risk
No initiatives are at risk or blocked.
Sources:none — derived from portfolio counts
Escalated risks
No risks are currently escalated.
Sources:none — derived from portfolio counts
Insights needing action
All Critical and High insights have been routed.
Sources:none — derived from portfolio counts
Publication milestones
No publication milestones are past due.
Sources:none — derived from portfolio counts
Decisions needed
1 decision require leadership attention: Approve Aurelin FY2026 medical plan v2.
Sources:DEC-0011